U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian CRO vivoPharm as it looks to bolster its offerings.

SynteractHCR named Frank Santoro, M.D., who has more than 30 years of experience and most recently was Novella Clinical’s CMO, as its CMO.

A BMJ paper has shown that progress is being made on clinical trial transparency, although there is still a way to go.

Takeda inked a multiyear, $170 million-per-program drug discovery partnership with Schrödinger.

A proof-of-concept study suggests that combines AI and the whole-genome sequencing of tumors could scale precision medicine for cancer.

Science Exchange will offer IndieBio-backed biotech startups access to its outsourced R&D platform.

The FDA and its new Trump-picked commissioner Scott Gottlieb took to social media to talk up plans to speed up the drug regulation process.

Neuroscience-focused digital technology company Ixico just nabbed a contract for imaging clinical trial services from Spanish biotech Araclon.